Kojima O, Oh A, Kitagawa N, Uehara Y, Nishioka B, Fujita Y, Majima S
Jpn J Surg. 1981;11(6):413-21. doi: 10.1007/BF02469024.
Leucocytes from patients with gastric cancer and other malignant and non-malignant diseases of the gastrointestinal tract as well as from healthy controls were tested for leucocyte migration inhibition test (LMI) using five different, allogeneic 3M KCl soluble extracts from gastric cancer tissues. The normal range of migration index (MI) was considered to be between 0.77 and 1.18 by calculating the mean MI +/- 2SD of ten healthy controls with cancer extracts. MIs out of this range were considered to be pathologic. In LMI test with a single tumor extract, pathologic MI was found in 48% of 79 gastric cancer patients, such being significantly higher than in those (4-21%) of three other groups of patients. In the panel mode of LMI, i.e., testing each blood sample with five different tumor extracts, 79% (62/79) of patients with gastric cancer were reactive, while 25% (5/20) of colorectal cancer patients showed "positive" reaction and no "positive" reactivity was observed in two other groups of patients. Thus, the "positive" reactivity in patients with gastric cancer was observed significantly higher than those in the other 3 groups of patients. Gastric cancer extracts had a wide range of cross-reactivity when compared with colorectal tumor extracts which showed a relatively restricted cross-reactivity. Thus, the LMI tests, particularly when tested by a panel mode, seems to express cell-mediated immunity against tumor associated antigens of gastric cancer.
使用来自胃癌组织的五种不同的同种异体3M KCl可溶性提取物，对胃癌患者以及胃肠道其他恶性和非恶性疾病患者的白细胞，以及健康对照者的白细胞进行白细胞迁移抑制试验（LMI）。通过计算10名使用癌症提取物的健康对照者的平均迁移指数（MI）±2SD，将迁移指数（MI）的正常范围视为0.77至1.18之间。超出此范围的MI被认为是病理性的。在使用单一肿瘤提取物的LMI试验中，79名胃癌患者中有48%发现病理性MI，这明显高于其他三组患者（4%-21%）。在LMI的组合模式中，即使用五种不同的肿瘤提取物检测每个血样，79%（62/79）的胃癌患者有反应，而25%（5/20）的结直肠癌患者显示“阳性”反应，其他两组患者未观察到“阳性”反应。因此，观察到胃癌患者的“阳性”反应明显高于其他三组患者。与显示相对有限交叉反应性的结直肠癌提取物相比，胃癌提取物具有广泛的交叉反应性。因此，LMI试验，特别是以组合模式进行测试时，似乎表达了针对胃癌肿瘤相关抗原的细胞介导免疫。
